| Geld/Brief | 4,84 € / 4,88 € |
| Spread | +0,83% |
| Schluss Vortag | 4,78 € |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief 4,76 € Tageshoch 4,76 € | |
| 52W-Tief 1,51 € 52W-Hoch 5,85 € | |
| Jahrestief 4,26 € Jahreshoch 5,50 € | |
| Umsatz in Mio. | - |
| Operatives Ergebnis (EBIT) in Mio. | -103,20 $ |
| Jahresüberschuss in Mio. | -95,88 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -0,48 $ |
| Gewinnrendite | -55,92% |
| Umsatzrendite | - |
| Return on Investment | -45,04% |
| Marktkapitalisierung in Mio. | 608,45 $ |
| KGV (Kurs/Gewinn) | -6,40 |
| KBV (Kurs/Buchwert) | 3,53 |
| KUV (Kurs/Umsatz) | - |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +80,54% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 4,72 € | +1,29% | 4,66 € | 23.02.26 | |
| Frankfurt | 4,76 € | -0,42% | 4,78 € | 08:03 | |
| München | 4,78 € | 0 % | 4,78 € | 08:01 | |
| Stuttgart | 4,76 € | -0,42% | 4,78 € | 07:53 | |
| L&S RT | 4,85 € | -0,21% | 4,86 € | 08:20 | |
| NYSE | 5,715 $ | +3,44% | 5,525 $ | 23.02.26 | |
| Nasdaq | 5,72 $ | +3,44% | 5,53 $ | 23.02.26 | |
| AMEX | 5,735 $ | +2,41% | 5,60 $ | 19.02.26 | |
| Tradegate | 4,84 € | -0,41% | 4,86 € | 20.02.26 | |
| Quotrix | 4,86 € | +0,41% | 4,84 € | 07:27 | |
| Gettex | 4,78 € | -0,83% | 4,82 € | 07:30 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 23.02.26 | 4,68 | 0 |
| 20.02.26 | 4,64 | 0 |
| 19.02.26 | 4,82 | 0 |
| 18.02.26 | 4,72 | 9.223 |
| 17.02.26 | 4,78 | 0 |
| 16.02.26 | 4,64 | 0 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 4,64 € | +2,16% |
| 1 Monat | 5,10 € | -7,06% |
| 6 Monate | 2,66 € | +78,20% |
| 1 Jahr | 2,56 € | +85,16% |
| 5 Jahre | 1,56 € | +203,85% |
| Marktkapitalisierung | 1,11 Mrd. € |
| Aktienanzahl | 203,47 Mio. |
| Streubesitz | 11,72% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +14,16% | NEA Management Company, LLC |
| +10,18% | Bain Capital Life Sciences Investors, LLC |
| +7,15% | TCG Crossover Management, LLC |
| +6,37% | Vestal Point Capital LP |
| +5,66% | BlackRock Inc |
| +5,14% | VR Adviser, LLC |
| +4,89% | Vanguard Group Inc |
| +4,82% | Nantahala Capital Management, LLC |
| +4,61% | Deerfield Management Co |
| +3,95% | Farallon Capital Management, L.L.C. |
| +2,08% | ADAR1 Capital Management LLC |
| +2,04% | Emerald Advisers, LLC |
| +1,94% | Wellington Management Company LLP |
| +1,72% | Geode Capital Management, LLC |
| +1,54% | Rosalind Advisors, Inc. |
| +1,42% | Sofinnova Ventures |
| +1,42% | State Street Corp |
| +1,26% | Emerald Mutual Fund Advisers Trust |
| +0,76% | Sphera Funds Management Ltd. |
| +0,65% | SUPERSTRING CAPITAL MANAGEMENT LP |
| +6,51% | Weitere |
| +11,72% | Streubesitz |
Zahlen für Q1/24
- Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024
- the Company Continues to Believe it is Sufficiently Capitalized into 2026
https://savarapharma.com/investors/press-releases/release/?id=14706
